We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Damage Control Laparotomy Beneficial in Trauma Patients

By HospiMedica International staff writers
Posted on 10 Jan 2011
Despite often leading to complications and readmissions, the overall benefit of performing damage control laparotomy (DCL) for trauma patients is indisputable, according to a new study.

Researchers at the University of Maryland (Baltimore, USA) conducted a prospective study of 88 patients who were admitted to a level-1 trauma center between January 1, 2000, and December 31, 2003; the patients underwent DCL and they were subsequently followed up through December 31, 2008. More...
The main outcome measures were major and long-term complications, lengths of stay, mortality, readmissions, subsequent surgical procedures, activities of daily living, and return to work.

The results showed that 42 of the patients had penetrating trauma; the others had blunt trauma injuries. Liver injuries were most common, followed by injuries to the bowel, spleen, major vessels and pancreas; 25 patients (28%) died during the initial hospitalization; of the 63 patients who survived, 58 underwent intra-abdominal closure with polyglactin mesh. All 63 survivors were readmitted at least once over an average follow-up of 4.3 years. The primary reason for hospital readmission was for ventral hernia repair, with infection the second most common reason; 51 patients required a second readmission, and 29 required a third. In all, they had 186 readmissions and 92 surgical procedures during the follow-up period, but all survived the rest of the study. The study was published early online on December 20, 2010, in Archives of Surgery.

"Despite the high rate of open abdomens after DCL, patients fared well with staged closures and had a very acceptable rate of recurrent hernia. Although all patients required readmission and reoperation, 0% mortality leaves no room for improvement,” concluded lead author Megan Brenner, MD, and colleagues. "The long-term survival and functional outcomes after DCL truly justify its high utilization of resources.”

DCL is the first of three phases of care for severely injured patients, with the aim of stopping the bleeding from the abdominal organs, not to repair the injuries. The second phase is expeditious surgical control of hemorrhage with temporary abdominal closure, and rewarming and resuscitation of the patient in an intensive care unit (ICU); the third phase, usually performed 24-72 hours after trauma, is definitive surgical repair.

Related Links:

University of Maryland



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.